GILD Stock Surges: Why Gilead Sees Its Oncology Business As A Force To Be Reckoned With

Gilead Sciences‘ (GILD) first-in-class cancer drug and GILD stock are finally hitting their stride.


The biotech company is an expert in a means of battling cancer by reprogramming a patient’s own cells with drugs called chimeric antigen receptor T-cell therapies, or CAR-T for short. But making bespoke drugs remains a challenge. For years, sales growth has missed expectations almost as much as it beat them — until 2022.

During the September quarter, sales from Gilead’s first drug…

Read More